Quick Facts

• Therapeutic Focus: Management of certain deficiencies in vitamin K activity.
• Key Indication: Supports correction of specific coagulation disorders.
• Potential Benefit: May help address hypoprothrombinemia linked to various factors.

---

Menadione, also known as vitamin K3, is a synthetic agent that functions as a precursor for the body's essential vitamin K compounds. The primary therapeutic use of menadione and its derivatives is to address conditions of hypoprothrombinemia (a low level of prothrombin), which is a specific type of blood clotting disorder.

This medication is used to support the maintenance of normal blood clotting function. This is especially relevant in cases where hypoprothrombinemia may be linked to a deficiency in vitamin K activity or interference with it, such as from the use of certain anticoagulant medications or prolonged antibacterial therapy. In some contexts outside of the United States, it is utilized as an agent for vitamin K deficiency and related coagulation deficits. The use of menadione is contingent on a patient's specific clinical needs, as determined by a qualified healthcare professional.

Menadione's official regulatory labeling strictly defines the populations who can and cannot use the medicine, primarily through absolute contraindications based on documented toxicity risks.

Groups Prohibited from Using Menadione

Use of Menadione is strictly contraindicated for several populations as documented by regulatory authorities. These include newborns and premature infants due to the high risk of causing severe complications such as hemolytic anemia and brain damage (kernicterus). The medicine is also contraindicated in patients with a confirmed diagnosis of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency because of the associated risk of inducing hemolysis. Additionally, use is prohibited in individuals with known hypersensitivity or allergy to Menadione.

Restricted and Conditional Eligibility

The official profile places significant limitations on use even among otherwise eligible populations. Use during pregnancy and lactation is generally not recommended unless the clinical need is determined to be absolutely essential. For patients with impaired organ function, regulatory labeling mandates extreme caution when administering Menadione to those with severe liver impairment or renal impairment. The standard eligible population is therefore limited to adults and older children without these specific contraindications or conditions.

Interactions with other medicines and products

The official interaction profile for Menadione is structured around its role as a prothrombogenic agent, leading to documented effects involving pharmacodynamic counteraction and pharmacokinetic constraints. All interaction patterns are detailed in authoritative government regulatory documents, focusing strictly on functional outcomes.

Officially Documented Drug Interactions

Interacting Substance/Class	Official Interaction Description
Oral Anticoagulants (Coumarin/Indanedione)	Menadione induces temporary resistance to the prothrombin-depressing action of these agents, an example of pharmacodynamic antagonism.
Heparin	Officially noted as a non-interaction; Menadione will not reverse the anticoagulant effect of heparin.
Salicylates / Antibacterial Agents	Used to counteract documented hypoprothrombinemia that is secondary to the administration of these product classes.

Exposure and Administration Constraints

Interaction with certain products can officially reduce Menadione’s systemic exposure. Fat Absorption Inhibitors, such as Orlistat and Bile Acid Sequestrants, interfere with the necessary gastrointestinal uptake of this fat-soluble provitamin. To mitigate this reduction in exposure, regulatory guidance specifies that Menadione administration must be separated from these inhibitors by a minimum of two hours. This timing rule is necessary to support adequate absorption.

A separate interaction-related caution addresses specific populations: regulatory documents note an increased risk of drug-induced haemolysis in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency following the administration of Vitamin K analogs.

Menadione acts as a provitamin, meaning it must first be metabolically converted into its active form, menaquinone-4 (MK-4). This active molecule then functions as an essential cofactor for the enzyme gamma-Glutamyl Carboxylase (GGCX) in the liver. This activation mechanism is necessary for the activity of the critical enzyme responsible for modifying clotting factors, setting the stage for subsequent clotting factor activation.

The activated GGCX enzyme catalyzes a crucial chemical reaction known as gamma-carboxylation on specific precursor proteins: Factors II, VII, IX, and X. This modification creates specialized Gla residues that allow the proteins to bind calcium ions (Ca^2+), which is the final step required for these factors to properly anchor to cell membranes and initiate the blood coagulation cascade.

The drug's physiological effect is not immediate because the mechanism is dependent on the time needed for the metabolic conversion to MK-4 and the synthesis and release of new, functional clotting factors by the liver. This time-dependent process means the mechanism results in a gradual, sustained increase in active clotting factor concentration rather than instantaneous factor activation.

How to Use Menadione

The usage of Menadione and its derivatives, such as Menadiol Diphosphate, is defined by established administration guidelines to support blood coagulation. Administration is categorized by the approved dosage form.

Administration and Dosage Patterns

Menadione is administered through Oral tablets or via Parenteral routes (intravenous, intramuscular, or subcutaneous injection) using solution forms of its water-soluble salts. The choice of route depends on the specific clinical scenario.

Usage Guideline	Typical Administration Detail
Standard Adult Dose	Oral: 10 mg to 40 mg total daily dose. Parenteral doses range from 2.5 mg to 10 mg per dose.
Frequency	Once daily or administered in divided doses up to three or four times per day.
Pediatric Dosing	A lower dose range of 5 mg to 20 mg daily is designated for children.

Older adults typically follow the standard adult dosing recommendations, as no specific adjustments are noted in standard labeling for this population.

Procedural Context

Oral tablet forms can sometimes be divided into equal doses if the product is scored, as specified in the product information. In contrast, parenteral forms, such as injectable solutions, require administration by a qualified healthcare professional in a controlled setting. The medicine is generally used as part of a short-term course aimed at restoring coagulation factor activity, rather than for long-term maintenance.

Research evidence / Overview of studies for Menadione

Research Evidence for Coagulation Deficits (Hypoprothrombinemia)

Research has shown that the foundation of evidence for Menadione is based on its study as a compound related to coagulation deficits. Early clinical research, primarily consisting of historical case reports and observational studies from the mid-20th century, examined the compound’s association with clotting factors. These studies included adult patients with impaired Vitamin K utilization. Studies monitored coagulation biomarkers such as Prothrombin Time (PT), which were outcomes related to systemic or functional imbalance. Findings describe patterns observed in the research where biomarker measurements were monitored following compound administration.

Comparative Research and Special Populations

Menadione was evaluated in specific groups, notably for the study of Vitamin K deficiency-related bleeding in newborns. Research in this area included double-blind randomized controlled trials (RCTs). Trials monitored outcomes using the PIVKA-II biomarker, an indicator of vitamin K deficiency. Findings describe patterns indicating that Menadione and the naturally occurring form (Phytonadione, or Vitamin K₁) were associated with similar reported measurements concerning PIVKA-II detection rates in healthy newborns.

Summary of Evidence Gaps and Limitations

The current body of evidence relies heavily on historical research. Modern, large-scale randomized controlled trials (RCTs) designed to compare Menadione against current standard therapies in broad adult populations are generally lacking. Follow-up durations were limited in many earlier studies, and the evidence for long-term outcomes over an extended period is not fully established. Comparative evidence is lacking for many adult populations, and data for certain groups, such as older adults with multiple health conditions, remain insufficient. Overall, the evidence highlights what is known—and what is still uncertain—about the compound's research profile.

Key Studies & References

1. Assessment of evidence base for therapeutic agents in acquired hypoprothrombinemia: A systematic review

Common questions about Menadione (FAQ)

Q: What are the most common mild side effects reported for Menadione?

Documented adverse effects listed in regulatory sources include nausea, vomiting, abdominal pain, diarrhea, and headache. Skin rash is also noted in official product information as a possible effect.

Q: Is it true that Menadione has been banned in some countries for human use?

Official health authority communications note that the use of Menadione in human medicine has been historically restricted. It is generally avoided in many developed countries due to established concerns about potential toxicity, particularly in newborns.

Q: What is the general safety classification of Menadione according to regulatory bodies?

While official documents do not typically use a simplified 'high-risk' or 'low-risk' term for patient information, they detail specific contraindications and toxicity risks. These mandatory restrictions, especially for vulnerable populations, underscore the need for cautious and restricted use.

Q: Are there known interactions between Menadione and common over-the-counter medications?

Official labeling mentions that Menadione can counteract the effects of certain antibacterial agents and salicylates, which are sometimes found in over-the-counter products. However, official product information does not provide a comprehensive list of every common over-the-counter medication.

Q: Are allergic reactions to Menadione common?

Hypersensitivity reactions (allergic reactions) are documented in official safety information. While very severe reactions, such as anaphylactic shock, are specifically described as rare, the frequency of all allergic reactions is not always detailed in summary regulatory documents.

Q: Is there any public safety announcement or warning about Menadione from the FDA or EMA?

Regulatory bodies consistently issue explicit warnings and contraindications related to Menadione. These official statements emphasize its strict prohibition for use in newborns and patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to safety risks.

Q: How is the need for Menadione determined by a healthcare provider?

The clinical need for this medicine is typically assessed by a healthcare provider. This assessment is supported by laboratory tests designed to measure the blood's ability to clot, such as monitoring the patient's Prothrombin Time (PT).

Q: Are there any specific monitoring requirements for patients using Menadione?

Official product information indicates that regular monitoring of the patient's clotting status is required during therapy. Specifically, this monitoring may involve checking the Prothrombin Time (PT), which measures how long it takes for a blood sample to clot.

Q: Does the package insert mention any specific food groups to avoid?

Official information states that Menadione administration must be separated from certain drug classes known as fat absorption inhibitors. However, official patient information does not generally list specific common food groups as contraindications.

Q: What should be done if someone misses a dose of Menadione?

Information about how to handle a missed dose is generally defined in the official Patient Information Leaflet. Typically, if the next dose is due soon, taking the missed dose is omitted to prevent over-administration.

Q: Are there any restrictions on driving or operating machinery while using Menadione?

Some safety sources often note that Menadione does not typically cause sleepiness or drowsiness, which is relevant to operating machinery. Although an explicit, universal warning regarding driving restrictions may not be standard, this information is available in some official documentation.

Q: Does official information list any interactions with caffeine or alcohol?

Official patient information notes that the interaction between Menadione and alcohol is currently either unknown or not available in the summary documentation. Information regarding caffeine is also generally not listed in product inserts.

Q: Does taking Menadione affect the absorption of other vitamins?

Official expert panel notes indicate that other fat-soluble vitamins may potentially compete with and interfere with Vitamin K absorption. However, information detailing Menadione specifically affecting the absorption of other vitamins is generally not found in human medicine labels.

Q: Is the use of Menadione linked to any specific environmental or occupational factors?

Regulatory guidance details environmental precautions that apply to the compound. This includes proper disposal procedures and ensuring the substance is kept away from drains.

Q: Can Menadione be used alongside mineral supplements like iron or calcium?

Official interaction data notes that Menadione may interact with certain compounds, including calcium.

Q: Is it normal to feel nauseous when taking Menadione?

Nausea and vomiting are listed among the documented side effects. Nausea is a documented side effect, and any persistent or severe symptoms are typically reviewed by a healthcare provider.

How to Store and Dispose of Menadione (Vitamin K₃)

Official regulatory guidelines define specific conditions to maintain the stability and integrity of menadione preparations.

Storage Requirement	Official Condition
Temperature	Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F to 86 F).
Protection	Must be protected from light and stored in a dry, well-ventilated area.
Container	Keep in the closed original container and ensure it is tightly closed.
Safety	Must be kept out of the sight and reach of children.

Disposal instructions mandate that unused or expired menadione should not enter drains or wastewater due to environmental restrictions. The preferred method for discarding the product is through established community drug take-back programs, adhering strictly to national and local waste regulations.